Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
The purpose of this study is to find optimum dosage of DW-3101 by evaluating efficacy and
 safety of each dosage group in Korean patients with acute and chronic gastric inflammation.
Inclusion Criteria:

 -  Adult males/females aged 20~75 years

 -  Patients detected over 1 erosion who diagnosed as acute or chronic gastric
 inflammation by gastrscopy in 7days before administration of experimental agents

 -  Subjects who voluntarily agree to participate in this clinical test with written
 consent

 Exclusion Criteria:

 -  Patients impossible gastroscopy

 -  In case accompanied with gastric ulcer(scar excepted) or reflux esophagitis

 -  Patients who had stomach or esophagus surgery to inhibit gastric acid secretion
 (tresis or appendicectomy surgery excluded)

 -  Patients with malignant tumor on digestive organ

 -  Patients with blood clot(cerebral thrombosis, myocardial infarction, septic
 thrombophlebitis) and who have antithrombotic agents (eg. warfarin)